Atmo Biosciences
Developed a solution to accurately profile the gases within the gut, leading to better diagnosis and treatment of gastrointestinal disorders.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD44—65m (Dealroom.co estimates Mar 2023.)
Company register number 626053183
Melbourne Victoria (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $3.5m | Seed | |
| N/A | AUD2.5m | Seed | |
AUD620k | Grant | ||
AUD9.6m | Early VC | ||
* | AUD343k | Grant | |
AUD29.3k | Grant | ||
* | $8.0m | Series B | |
* | N/A | Late VC | |
| Total Funding | CAD27.2m | ||
Related Content
Recent News about Atmo Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.